Skip to main navigation Skip to search Skip to main content

Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control

  • Stephene S. Meena
  • , Benson K. Kosgei
  • , Geofrey F. Soko
  • , Cheng Tingjun
  • , Ramadhani Chambuso
  • , Julius Mwaiselage
  • , Ray P.S. Han
  • Jiangxi University of Traditional Chinese Medicine
  • Ocean Road Cancer Institute
  • Harvard University
  • University of Cape Town

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Tumor-derived exosomes (TDEs) mediate oncogenic communication, which modifies target cells to reinforce a tumor-promoting microenvironment. TDEs support cancer progression by suppressing anti-tumor immune responses, promoting metastasis, and conferring drug resistance. Thus, targeting TDEs could improve the efficacy of anti-cancer treatments and control metastasis. Current strategies to inhibit TDE-mediated oncogenic communication including drug-based and genetic modification-based inhibition of TDE release and/or uptake, have proved to be inefficient. In this work, we propose TDE surface engineering to express foreign antigens that will trigger life-long anti-TDE immune responses. The possibility of combining the anti-TDE vaccines with other treatments such as chemotherapy, radiotherapy, targeted therapy, and surgery is also explored.

Original languageEnglish
Article number18
Journalnpj Vaccines
Volume10
Issue number1
DOIs
StatePublished - Dec 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control'. Together they form a unique fingerprint.

Cite this